Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Programs
Steven K. Grinspoon, MD is a clinician in the Neuroendocrine and Pituitary Tumor Clinical Center and a faculty member in the Neuroendocrine Unit at the Massachusetts General Hospital, and a Professor of Medicine at Harvard Medical School. He is a clinical researcher who studies hypothalamic control of body weight and fat distribution in obesity and lipodystrophy with a focus on the metabolic and cardiovascular consequences of visceral fat accumulation. Awards in recognition of his work have included selection to the American Society for Clinical Investigation, the Association of American Physicians and the 2014 Daniel Ahrens Award for Translational Science Research by the Association of Clinical and Translational Science. He is the author of more than 200 peer-reviewed publications and serves as the Director of the Nutrition Obesity Research Center at Harvard and as the Director of the MGH Program in Nutritional Metabolism.
One year ago, the National Institutes of Health launched REPRIEVE – The Randomized Trial to Prevent Vascular Events in HIV study, designed to investigate whether statin use can prevent cardiovascular disease in people living with HIV. To date, the trial has enrolled nearly 1,200 participants across approximately 85 trial sites.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at the MGH, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand.
A nationwide study based at MGH will investigate, for the first time, whether treatment with a statin drug can reduce the elevated risk of cardiovascular disease in individuals infected with the human immunodeficiency virus.
The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients.
An MGH research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men.
The elevated risk of cardiovascular disease seen in patients infected with HIV appears to be associated with increased inflammation within the arteries, according to a study in a special issue of JAMA published in conjunction with the International AIDS Conference.
Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV.
Back to Top